FDA Clears Path for First Human Clinical Trial of Mitragynine as Opioid Use Disorder Treatment

Why it matters

The first FDA-cleared human trial of mitragynine — kratom's primary alkaloid — represents a milestone in understanding whether a purified kratom compound could expand treatment options for opioid use disorder, which kills tens of thousands of Americans each year.

The big picture

The NIH and University of Florida obtained FDA approval for an Investigational New Drug (IND) application to study purified mitragynine in human volunteers with recent opioid use histories. This is a Phase 1 safety study — not a treatment approval — and uses a lab-purified form that is distinct from commercial kratom products. The announcement has generated both optimism from kratom advocates and concern from addiction specialists who note kratom's own dependency potential.

Key findings

• The FDA approved an IND application allowing a Phase 1 human safety study of purified mitragynine developed by NIH/University of Florida researchers
• The trial will enroll 32 healthy volunteers with recent histories of opioid use to test safety and tolerability — not efficacy
• The experimental compound is a lab-purified mitragynine formulation, distinct from commercially sold kratom products which vary widely in alkaloid content
• NIH researchers developed the formulation after preclinical animal studies showed no significant safety signals at multiple dose levels
• A 2022 NIH survey found approximately one-third of kratom users met criteria for kratom use disorder, raising questions about the compound's own dependency potential
• The FDA has not approved kratom and continues to seize commercial kratom shipments under Import Alert 54-15

What they say

Dr. Nora Volkow, former director of NIH's National Institute on Drug Abuse, called it 'a major step toward expanding treatment options' for opioid use disorder.

Bottom line

**The FDA's approval of a human safety trial for purified mitragynine marks a significant research milestone — but the early-stage study tests only safety and tolerability, not whether kratom's primary alkaloid actually works as an addiction treatment.**